AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$VNDA

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Vanda Pharmaceuticals reported Q3 sales of $7.7M for PONVORY, up 10% YoY, and $1.6M for NEREUS, up 60% QoQ. The company expects to launch BYSANTI in Q4 2026 and anticipates $240M+ in full-year 2026 revenue. Operating expenses decreased sequentially to $93.3M, while cash balance fell to $140.5M. Vanda plans FDA discussions for NEREUS and HETLIOZ applications.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vanda Pharmaceuticals Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$VNDANeutralMed
01

Why it matters

Guidance lift may provide short‑term price support, but cash burn and modest sales temper enthusiasm.

02

Market read

First report of Vanda's Q3 numbers and updated guidance; relevant for biotech investors.

03

What to watch

Potential regulatory delays for BYSANTI and HETLIOZ could affect future revenue.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Vanda Pharmaceuticals reported Q3 results, highlighted product sales, upcoming launches, and raised its full‑year revenue outlook.

Company-level read

Ticker impact

$VNDANeutralHigh confidence
Context

Q3 earnings call disclosed $7.7M PONVORY sales, raised full-year revenue outlook to >$240M and announced upcoming BYSANTI launch.

Expected impact

potential modest upside as market prices in higher revenue outlook, tempered by cash burn concerns

Evidence & confidence

New guidance and product launch timeline are primary disclosures; investors will reassess valuation.

Market effects

Sector

Higher CNS drug pipeline activity may benefit peer biotech sector.

Regional

U.S. biotech market sees modest uplift from Vanda's guidance.

Global

Limited to investors tracking small‑cap pharma stocks.

Counterpoint

What could challenge this read

Cash burn acceleration could pressure the stock despite revenue raise.

Key entities

  • company
    Vanda Pharmaceuticals

    Biopharma focused on CNS disorders, ticker VNDA.

Read at source← All news

StoryVanda Pharmaceuticals posts Q3 2026 revenue up 24% and raises full‑year guidance above $240 M

Also covered by

4 outlets

Related articles

$VNDAMed

H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth

H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.

investing.com
$VNDAMed

Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24%

Vanda Pharmaceuticals reported a 24% revenue increase in Q3 2026, but net loss widened to $133.6M for the first nine months. Hetlios sales declined 21% due to generic competition, and Nereus revenue is expected to be less than $10M for 2026. Cash reserves decreased by $123.4M. The company anticipates FDA decisions on Quimilza and Bisanti in 2027. CEO Mihael Polymeropoulos discussed commercial plans and clinical trial updates during the earnings call.

finance.yahoo.com
$VNDAMed

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.

hcplive.com
$VNDAMed

Vanda (VNDA) Q3 2026 Earnings Call Transcript

Vanda Pharmaceuticals (VNDA) reported Q3 2026 earnings, with revenue up 24% YoY to $172.1M for the first nine months, driven by Fanapt's growth and NEREUS launch. Operating expenses decreased 18% QoQ. Key drugs like BYSANTI, Quimilza, and HETLIOZ are in various stages of FDA review and clinical trials. Fanapt saw a 25% increase in prescriptions, while HETLIOZ faced generic competition.

finance.yahoo.com
$VNDAMed

Vanda: Q3 Earnings Snapshot

Vanda Pharmaceuticals (VNDA) reported a Q3 loss of $22.6M or 37 cents per share, beating analyst estimates of a 72 cents loss. Revenue was $69.8M, exceeding forecasts of $65.9M. The company expects full-year revenue of $240M.

finance.yahoo.com